Molbio Diagnostics Limited has successfully secured ₹939.696 crore through an initial public offering (IPO) of equity shares, which included both a fresh issue and an offer for sale. The IPO marks a significant milestone for the company, which is renowned for its innovative point-of-care diagnostics solutions.
Legal Teams Steering the IPO
Khaitan & Co played a pivotal role in advising Molbio Diagnostics on this substantial IPO. The legal expertise was provided by a dedicated team comprising Abhimanyu Bhattacharya, Gautham Srinivas, and Sathvik Ponnappa, all partners at the firm, alongside Principal Associate Sanjeev Chowdhary, Senior Associate Vaishnavi Gupta, and Associates Mainak Pani and Shambhavi Gautam.
Cyril Amarchand Mangaldas offered their legal counsel to the book-running lead managers, which included Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited. The transaction was spearheaded by Senior Partner Yash J. Ashar and Partner Priyadarshini Rao, with key contributions from Senior Associate Raksha Raina and Associates Prakhar Jain, Janhavi Deshmukh, Zubin Ronnie, Aria Sheth, and Namita Kaushik.
International counsel was provided by Hogan Lovells Cadwalader, with Biswajit Chatterjee, the Head of the India Practice and Dubai Office Managing Partner, leading their team.
Molbio Diagnostics: An Innovator in Healthcare
Molbio Diagnostics, a pioneering company in point-of-care (POC) diagnostics, focuses on enhancing access to precise, rapid, and affordable healthcare technologies. Their flagship product, Truenat, is a groundbreaking POC polymerase chain reaction (PCR) platform. Notably, this battery-operated device is designed to function in resource-constrained environments, enabling decentralized diagnosis in under an hour.
The IPO witnessed remarkable interest, being subscribed 70.26 times, with the section allocated for qualified institutional buyers seeing a subscription rate of 186.39 times. This high demand underscores the confidence in Molbio’s innovative capabilities and growth potential.
Utilization of IPO Proceeds
The capital raised from the IPO will be strategically utilized to bolster Molbio’s research and development facility, establish a Centre of Excellence, and enhance office infrastructure. Additionally, investments will be made in plant, machinery, and equipment for their manufacturing units, alongside general corporate purposes.
For those interested in having their deals, columns, or press releases featured on Bar & Bench, submissions can be made through the form available on their website.
